AVEO लाइव सिग्नल्स | Getagraph.com के साथ लाभ को अधिकतम करें

Live Chart Being Loaded With Signals

Commentary (20 Jan 2023 @ 02:30):

Stats
आज की मात्रा	245 298
औसत मात्रा	564 056
बाजार मूल्य	0.00
EPS	$0 ( 2023-03-13 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0.0560 (0.37%)

Insider Trading

Date	Person	Action	Amount	type
2023-01-19	Bate Kenneth	Sell	375	Common Stock
2023-01-19	Bate Kenneth	Sell	22 500	Stock Option (Right to Buy)
2023-01-19	Evnin Anthony B	Sell	22 500	Stock Option (Right to Buy)
2023-01-19	Ledell Jebediah	Sell	27 702	Stock Option (Right to Buy)
2023-01-19	Ferraresso Michael	Sell	220 000	Stock Option (Right to Buy)

INSIDER POWER
46.33
Last 96 transactions
Buy: 43 011 518 \| Sell: 9 966 796

मात्रा सहसंबंध

लंबा: 0.17 (neutral)

छोटा: 0.33 (neutral)

Signal:(73.104) Neutral

Aveo Pharmaceuticals Inc सहसंबंध

10 सबसे अधिक सकारात्मक सहसंबंध
BNIXU	0.861
MACQU	0.804

10 सबसे अधिक नकारात्मक सहसंबंध
EVGN	-0.874
MTC	-0.839
RAAC	-0.802
ISRG	-0.801

क्या आप जानते हैं?

कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।

कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।

Aveo Pharmaceuticals Inc सहसंबंध - मुद्रा/वस्त्र

-0.59
( weak negative )

0.28
( neutral )

0.40
( neutral )

-0.24
( neutral )

-0.86
( strong negative )

0.55
( weak )

Aveo Pharmaceuticals Inc वित्तीय

Annual	2021
राजस्व:	$38.87M
सकल लाभ:	$34.14M (87.81 %)
EPS:	$-2.49

FY	2021
राजस्व:	$38.87M
सकल लाभ:	$34.14M (87.81 %)
EPS:	$-2.49

FY	2020
राजस्व:	$6.02M
सकल लाभ:	$4.77M (79.32 %)
EPS:	$-1.660

FY	2019
राजस्व:	$28.80M
सकल लाभ:	$0.00 (0.00 %)
EPS:	$0.610

Financial Reports:

No articles found.

Aveo Pharmaceuticals Inc

AVEO Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients. It markets its lead candidate, FOTIVDA, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC); and tivozanib for the treatment of RCC, HCC, immunologically cold tumors, and CCA. The company has also completed a Phase II clinical trial of tivozanib in combination with Opdivo (nivolumab) for the treatment of RCC. In addition, it is developing Ficlatuzumab, a potent humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets hepatocyte growth factor that is in a Phase II clinical trial for the treatment of squamous cell carcinoma of the head and neck, pancreatic cancer, and acute myeloid leukemia; AV-203, a potent humanized IgG1 monoclonal antibody, which completed Phase I clinical trial for treating human ErbB3; and AV-380, a potent humanized IgG1 inhibitory monoclonal antibody that is in a Phase I clinical trial for the treatment or prevention of cachexia. The company's preclinical stage product includes AV-353 that targets the Notch 3 pathway. AVEO Pharmaceuticals, Inc. has collaboration agreements with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. Vincent's Hospital Sydney Limited; Biogen Idec International GmbH; Kyowa Kirin Co., Ltd.; and AstraZeneca PLC. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts.